US · RMTI · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Rockwell Medical, Inc. (RMTI) intrinsic value and stock valuation
$5.82as of 2026-11-21 · Mkt cap 28.66M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Rockwell Medical, Inc. DCF and intrinsic value
InvestorsCraft values RMTI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RMTI’s statements →
Rockwell Medical, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Cumberland Pharmaceuticals Inc. (CPIX) $5.84
- Alterity Therapeutics Limited (ATHE) $1.52
- Star Equity Holdings, Inc. (STRR) $8.30
- Talphera, Inc. (TLPH) $0.79
- Evaxion Biotech A/S (EVAX) $2.25
- Quantum BioPharma Ltd. (QNTM) $1.29
- NeuroOne Medical Technologies Corporation (NMTC) $0.65
- Liminatus Pharma, Inc. Class A Common Stock (LIMN) $2.51
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $69.3M | $101.5M | $83.6M | $72.8M | $61.9M |
| Operating income | -$-4.69M | $610K | -$-6.67M | -$-16.78M | -$-30.34M |
| Net income | -$-5.31M | -$-480K | -$-8.44M | -$-18.68M | -$-32.67M |
| EPSd | -$-1.47M | -$-154.34K | -$-3.62M | -$-18.87M | -$-38.44M |
| Operating cash flow | -$-660K | $4.2M | -$-9.41M | -$-16.93M | -$-33.53M |
| Capital expenditure | -$-540K | -$-1.01M | -$-280K | -$-280K | -$-520K |
| Free cash flow | -$-1.2M | $3.19M | -$-9.7M | -$-17.21M | -$-34.06M |
| Total assets | $57.2M | $59.2M | $52.2M | $46.6M | $48.6M |
| Total debt | $12.5M | $13.5M | $13.4M | $16.4M | $28.9M |
| Net debt | $1.76M | -$-2.13M | $4.46M | $6.26M | $15.6M |
| Total equity | $37M | $32.6M | $21.3M | $14.1M | $2.54M |
| Cash and short-term investments | $25M | $21.6M | $10.9M | $21.5M | $22.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $69.3M | $101.5M | $83.6M | $72.8M | $61.9M |
| Cost of revenue | $57.6M | $84M | $74.9M | $68.7M | $64.4M |
| Gross profit | $11.7M | $17.5M | $8.7M | $4.08M | -$-2.42M |
| Research and development expenses | $0.00 | $20K | $1.11M | $3.12M | $6.83M |
| Selling, general and administrative expenses | $16.4B | $16.9M | $14.3M | $17.7M | $21.1M |
| Other expenses | -$-16.37B | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $16.4M | $16.9M | $15.4M | $20.9M | $27.9M |
| Cost and expenses | $74M | $100.9M | $90.3M | $89.6M | $92.3M |
| Interest income | $230K | $90K | $210K | $30K | $20K |
| Interest expense | $1.12M | $1.25M | $2.3M | $1.94M | $2.36M |
| Depreciation and amortization | $2.19M | $2.18M | $1.44M | $580K | $2.52M |
| Ebitda | -$-2M | $2.95M | -$-4.69M | -$-16.17M | -$-27.8M |
| Operating income | -$-4.69M | $610K | -$-6.67M | -$-16.78M | -$-30.34M |
| Total other income/expenses, net | -$-620K | -$-1.09M | -$-1.77M | -$-1.9M | -$-2.34M |
| Income before tax | -$-5.31M | -$-480K | -$-8.44M | -$-18.68M | -$-32.67M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-5.31M | -$-480K | -$-8.44M | -$-18.68M | -$-32.67M |
| Weighted average shares outstanding | $3.6M | $3.11M | $2.33M | $990K | $850K |
| Weighted average diluted shares outstanding | $3.6M | $3.11M | $2.33M | $990K | $850K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $25M | $21.6M | $10.9M | $21.5M | $22.4M |
| Net receivables | $8.14M | $8.29M | $10.9M | $6.26M | $5.91M |
| Inventory | $3.42M | $5.78M | $5.87M | $5.81M | $4.08M |
| Total current assets | $38.2M | $37M | $28.8M | $35.3M | $35.3M |
| Property, plant and equipment, net | $7.85M | $10.3M | $11M | $8.61M | $10.2M |
| Goodwill and intangible assets | $10.6M | $11.1M | $11.7M | $920K | $920K |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $19M | $22.2M | $23.4M | $11.3M | $13.3M |
| Total assets | $57.2M | $59.2M | $52.2M | $46.6M | $48.6M |
| Accounts payable | $2M | $2.87M | $4.52M | $4.05M | $3.74M |
| Short-term debt | $1.89M | $2.43M | $2.18M | $4.14M | $9.82M |
| Deferred revenue | $360K | $140K | $290K | $1.8M | $2.31M |
| Total current liabilities | $9.58M | $14.1M | $16.6M | $17.7M | $21M |
| Long-term debt | $10.6M | $11.1M | $11.3M | $12.2M | $19.1M |
| Deferred revenue, non-current | $0.00 | $430K | $470K | $2.6M | $5.99M |
| Total non-current liabilities | $10.6M | $12.5M | $14.2M | $14.8M | $25.1M |
| Capital lease obligations | $3.38M | $4.79M | $4.9M | $6.67M | $7.89M |
| Total liabilities | $20.2M | $26.6M | $30.9M | $32.5M | $46M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-402.99M | -$-397.68M | -$-397.2M | -$-388.76M | -$-370.08M |
| Accumulated other comprehensive income (loss) | $130K | $50K | -$0.00 | $160K | $50K |
| Total equity | $37M | $32.6M | $21.3M | $14.1M | $2.54M |
| Total investments | $14.3M | $5.94M | $1.95M | $11.4M | $9.16M |
| Total debt | $12.5M | $13.5M | $13.4M | $16.4M | $28.9M |
| Net debt | $1.76M | -$-2.13M | $4.46M | $6.26M | $15.6M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-5.31M | -$-480K | -$-8.44M | -$-18.68M | -$-32.67M |
| Depreciation and amortization | $2.19M | $2.18M | $1.44M | $580K | $2.52M |
| Stock-based compensation | $1.82M | $1.29M | $930K | $320K | $940K |
| Change in working capital | -$-1.61M | -$-1.53M | -$-7.24M | -$-2.13M | -$-4.84M |
| Accounts receivable | -$-100K | $2.61M | -$-4.64M | -$-350K | -$-1.74M |
| Inventory | $2.78M | -$-330K | $1.18M | -$-2.1M | -$-660K |
| Accounts payable | -$-870K | -$-1.65M | $460K | $310K | -$-420K |
| Net cash provided by operating activities | -$-660K | $4.2M | -$-9.41M | -$-16.93M | -$-33.53M |
| Investments in property, plant and equipment | -$-540K | -$-1.01M | -$-280K | -$-280K | -$-520K |
| Acquisitions, net | $0.00 | $0.00 | -$-12.36M | $0.00 | -$-830K |
| Net cash used for investing activities | -$-8.54M | -$-4.87M | -$-3.04M | -$-2.4M | $310K |
| Common stock issued | $7.82M | $10.2M | $14.9M | $15M | $110K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | -$-10K |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $4.25M | $7.35M | $11.3M | $16.2M | -$-2.18M |
| Net change in cash | -$-4.95M | $6.68M | -$-1.12M | -$-3.18M | -$-35.4M |
| Cash at end of period | $10.7M | $15.7M | $8.98M | $10.1M | $13.3M |
| Operating cash flow | -$-660K | $4.2M | -$-9.41M | -$-16.93M | -$-33.53M |
| Capital expenditure | -$-540K | -$-1.01M | -$-280K | -$-280K | -$-520K |
| Free cash flow | -$-1.2M | $3.19M | -$-9.7M | -$-17.21M | -$-34.06M |
Line items
Line items
Line items
About Rockwell Medical, Inc.
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
- CEO
- Mark Strobeck
- Employees
- 157
- Beta
- 1.61
Explore
Frequently asked questions
What is the intrinsic value of Rockwell Medical, Inc. (RMTI)?
InvestorsCraft does not currently publish an intrinsic value for RMTI. How the IC value is calculated.
Is RMTI undervalued?
InvestorsCraft does not publish an undervaluation signal for RMTI at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.